Determinación de la seguridad hepatorrenal del cannabidiol (CBD) durante el postoperatorio en caninos

In small animal clinics, the use of new alternatives with analgesic and anti- inflammatory properties, such as cannabidiol (CBD), offers a novel therapeutic prospect with fewer organic repercussions than NSAIDs and opioids. The aim of this experiment was to determine the hepatorenal safety of cannabidiol (CBD) in the postoperative period in dogs. To this end, 21 female dogs undergoing OFSH were tested for the potential adverse effects of CBD administered orally and sublingually, through measurements of hepatic and renal biomarkers, as well as the anti-inflammatory and analgesic spectrum assessed with measurements of C- reactive protein (CRP) and the Glasgow and Melbourne pain scales. This research concluded that CBD administered orally or sublingually did not cause clinically significant changes in liver and kidney analytes, therefore, its administration is considered safe in the postoperative period. In addition, the Glasgow and Melbourne postoperative pain scales showed that oral and sublingual CBD significantly reduced postoperative pain in the short and medium term. We also postulate that CBD is a good anti-inflammatory prospect, considering that in this experiment no statistically significant differences (P > 0.05) were established by determining C-reactive protein. Therefore, based on its therapeutic behavior, it may be a promising analgesic and anti-inflammatory resource.

• Main Author: Alban Moposita, Patricio Xavier (author)
• Other Authors: Armijos Moposita, Jonathan Alejandro (author)
• Format: bachelorThesis
• Published: 2025
• Subjects: CBD; HEPATORRENAL; DOLOR; PCR; ORAL; SUBLINGUAL
• Online Access: https://dspace.ueb.edu.ec/handle/123456789/8610